{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:13:26Z","timestamp":1787026406280,"version":"build-2736575974"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The year 2025 has been a transformative moment in GU oncology, with paradigm-shifting clinical trial results presented at major conferences and rapidly published. These developments are recasting therapeutic standards across bladder, kidney, prostate, penile, and testicular cancers through novel mechanisms and refined personalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This systematic review aimed to identify, synthesize, and critically evaluate pivotal phase II and III randomized controlled trials presented at ASCO\/ESMO 2025 or published in 2025, focusing on innovative therapeutic strategies across GU malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Conducted per PRISMA 2020 guidelines, the review involved exhaustive searches of conference proceedings, PubMed\/MEDLINE, and Embase (January-December 2025). Included studies were phase II and III RCTs in GU oncology reporting overall or progression-free survival for novel therapies. Study selection, data extraction, and risk-of-bias assessment using the Cochrane RoB 2 tool were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty studies met inclusion criteria: bladder cancer (13), kidney cancer (9), prostate cancer (16), testicular cancer (1), and penile cancer (1). Key advances include: (1) In bladder cancer, perioperative durvalumab (NIAGARA) and enfortumab vedotin plus pembrolizumab (KEYNOTE-905\/EV-303) set new standards, while HER2-targeted disitamab vedotin plus toripalimab (RC48-C016) improved metastatic survival. Upfront MRI staging (BladderPath) and kidney-sparing approaches (DISTINCT-I) advanced. (2) In kidney cancer, adjuvant durvalumab (RAMPART) and transcriptomic-guided therapy (OPTIC RCC) were established. LenCabo compared post-immunotherapy regimens, and FRUSICA-2 introduced a novel VEGF-TKI\/IO combination. (3) In prostate cancer, enzalutamide plus leuprolide improved survival in high-risk biochemical recurrence (EMBARK). Capivasertib plus abiraterone benefited PTEN-deficient metastatic hormone-sensitive disease (CAPItello-281). The PSMAddition trial demonstrated that adding [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 to standard therapy significantly improved radiographic PFS in PSMA-positive mHSPC. Docetaxel scheduling was optimized (ARASAFE), and an AI model (STAMPEDE) identified patients for AR inhibitor benefit. Novel agents like saruparib and pasritamig showed promise. (4) In testicular cancer, de-escalated therapy was established for seminoma (SAKK 01\/10). (5) In penile cancer, chemotherapy optimization progressed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The 2025 evidence establishes multiple new standards of care across GU cancers, emphasizing biomarker-driven strategies, immunotherapy integration, novel resistance mechanisms, and treatment optimization. This synthesis provides an evidence-based framework for updating guidelines and highlights the move toward more personalized management, while noting persistent challenges and future research needs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1780259","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:35:28Z","timestamp":1775018128000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Redefining standards: a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025"],"prefix":"10.3389","volume":"17","author":[{"given":"Nabil","family":"Ismaili","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Mohammed VI Foundation of Sciences and Health (FM6SS)","place":["Casablanca, Morocco"]},{"name":"Oncopathology, Biology and Environment of Cancer Laboratory, Mohammed VI Center for Research and Innovation (CM6RI), Mohammed VI Foundation of Sciences and Health (FM6SS)","place":["Rabat, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2026","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S1652","DOI":"10.1016\/j.annonc.2025.09.130","article-title":"LBA111 Randomized comparison of upfront magnetic resonance imaging versus transurethral resection for staging new bladder cancers: Final survival analysis from the BladderPath trial","volume":"36","author":"James","year":"2025","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4503","article-title":"Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA","volume":"43","author":"Powles","year":"2025","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.129","article-title":"LBA110 A blinded, exploratory phase II trial of nivolumab and the GDF-15 neutralizing antibody visugromab or placebo as neoadjuvant treatment of patients with muscle-invasive bladder cancer (MIBC): Primary results of the GDFather-NEO trial","volume":"36","author":"Necchi","year":"2025","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.131","article-title":"LBA112 Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC): SunRISe-4 (SR-4) primary analysis and biomarker results","volume":"36","author":"Necchi","year":"2025","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S1485","DOI":"10.1016\/j.annonc.2025.08.3685","article-title":"3071MO Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial","volume":"36","author":"Huang","year":"2025","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(25)00158-5","article-title":"Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study","volume":"26","author":"Gupta","year":"2025","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4500","article-title":"Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial","volume":"43","author":"Van Der Heijden","year":"2025","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S1649","DOI":"10.1016\/j.annonc.2025.09.125","article-title":"LBA7 Disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la\/mUC) with HER2-expression","volume":"36","author":"Sheng","year":"2025","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4501","article-title":"Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): Interim analysis from the JAVELIN Bladder Medley phase 2 trial","volume":"43","author":"Hoffman-Censits","year":"2025","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.011","article-title":"Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial","volume":"37","author":"Powles","year":"2026","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S1635","DOI":"10.1016\/j.annonc.2025.09.110","article-title":"LBA93 First results from RAMPART: An international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL","volume":"36","author":"Larkin","year":"2025","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.112","article-title":"LBA95 Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: The randomized phase II NESCIO trial","volume":"36","author":"Burgers","year":"2025","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.02.017","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial","author":"Choueiri","year":"2026","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S1298","DOI":"10.1016\/j.annonc.2025.08.3207","article-title":"2591O Efficacy of cabozantinib and nivolumab in cluster 1\/2 metastatic clear cell renal cell carcinoma: Results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker","volume":"36","author":"Haake","year":"2025","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4516","article-title":"Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated on the phase 3 PDIGREE (Alliance A031704) trial: Results from Step 1 analysis","volume":"43","author":"Zhang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S1307","DOI":"10.1016\/j.annonc.2025.08.3216","article-title":"2605MO Final efficacy data and biomarker analysis from the clear cell cohort of CALYPSO","volume":"36","author":"Coca Membribes","year":"2025","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.009","article-title":"A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)","volume":"37","author":"Hahn","year":"2026","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.3208","article-title":"2592MO Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): Results from phase III part of a randomized, open-label, active-controlled phase II\/III study (FRUSICA-2)","volume":"36","author":"Ye","year":"2025","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4521","article-title":"AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE\/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study","volume":"43","author":"Cost","year":"2025","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.102","article-title":"LBA86 Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)","volume":"36","author":"Nguyen","year":"2025","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5000","article-title":"Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer","volume":"43","author":"DeWeese","year":"2025","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.landig.2025.100885","article-title":"External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol","volume":"7","author":"Parker","year":"2025","journal-title":"Lancet Digit Health"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.103","article-title":"LBA87 EMBARK: Overall survival with enzalutamide in biochemically recurrent prostate cancer","volume":"36","author":"Shore","year":"2025","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S1630","DOI":"10.1016\/j.annonc.2025.09.104","article-title":"LBA88 Final results from PRESTO: A phase III open-label study of combined androgen blockade in patients (pts) with high-risk biochemically relapsed prostate cancer (BRPC) (AFT-19)","volume":"36","author":"Aggarwal","year":"2025","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5014","article-title":"Intensified hormonal blockade with SBRT in PSMA-PET detected oligometastatic prostate adenocarcinoma: Results from the phase II Metacure trial cohorts B2 and the B2 expansion","volume":"43","author":"Bent","year":"2025","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5005","article-title":"ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"43","author":"Armstrong","year":"2025","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5006","article-title":"Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes","volume":"43","author":"Attard","year":"2025","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","article-title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.3035","article-title":"2420MO Effects of prostate radiotherapy (RT) on synchronous, metastatic, hormone-sensitive prostate cancer (mHSPC): STOPCAP meta-analysis of individual participant data (IPD)","volume":"36","author":"Godolphin","year":"2025","journal-title":"Ann Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"S1633","DOI":"10.1016\/j.annonc.2025.09.108","article-title":"LBA92 3-weekly docetaxel 75 mg\/m\u00b2 vs 2-weekly docetaxel 50 mg\/m\u00b2 in combination with darolutamide + ADT in patients with mHSPC: Results from the randomised phase III ARASAFE trial","volume":"36","author":"Grimm","year":"2025","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5004","article-title":"Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial","volume":"43","author":"Morgans","year":"2025","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.101","article-title":"LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)","volume":"36","author":"Tagawa","year":"2025","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5019","article-title":"Exploratory analyses of homologous recombination repair alterations (HRRm) by gene subgroup and potential associations with efficacy in the HRR-deficient population from TALAPRO-2","volume":"43","author":"Zschaebitz","year":"2025","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS279","article-title":"Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01)","volume":"43","author":"Azad","year":"2025","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00678","article-title":"Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: A phase I study","volume":"43","author":"Stein","year":"2025","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"S658","DOI":"10.1016\/j.annonc.2025.08.1679","article-title":"1038MO Single-dose carboplatin and involved-node radiotherapy for seminoma stage IIA\/B: Long-term follow-up from the international multicenter phase II trial SAKK 01\/10","volume":"36","author":"Papachristofilou","year":"2025","journal-title":"Ann Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5012","article-title":"An open label randomized non-inferiority trial comparing adjuvant platinum plus paclitaxel to platinum plus 5-FU after curative resection in high-risk penile carcinoma","volume":"43","author":"Dhanawat","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1780259\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:35:45Z","timestamp":1775018145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1780259\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":41,"alternative-id":["10.3389\/fendo.2026.1780259"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1780259","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1780259"}}